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INTRODUCTION 
The development of effective endocrine therapies for the manage-
ment of early and advanced breast cancer has for a long time
focused on modifying the response of hormone-sensitive tumours
to circulating oestrogens. In theory, this endocrine manipulation
can be performed at a variety of levels: altering circulating levels
of oestrogens, modifying ligand binding to the oestrogen receptor
(ER) and adapting downstream responses as a consequence of
ligand binding to the ER. 
These differing approaches have led to the development of the most
widely used agents, the nonsteroidal antioestrogens – alternatively
described as selective oestrogen receptor modulators (SERMs)
(Kauffman and Bryant, 1995). Much of our clinical experience of
antioestrogens has been gleaned from the use of tamoxifen
(NolvadexTM). Tamoxifen has been available for more than 25
years (Early Breast Cancer Trialists’ Collaborative Group, 1992)
and during this period has become established as the first-choice
endocrine therapy for the management of postmenopausal women
with hormone-sensitive early and advanced breast cancer. Recent
clinical evidence has shown that tamoxifen also reduces the risk of
breast cancer (Fisher et al, 1998), on the basis of which it is now
licensed in the USA for use in patients considered to be at high risk
of developing primary breast cancer. 
The clinical experience of tamoxifen is very extensive with the
equivalent of about 8 million patient years of exposure during the
last 25 years. In the adjuvant setting, tamoxifen treatment provides
significant reductions to both tumour recurrence rates and overall
mortality (Early Breast Cancer Trialists’ Collaborative Group,
1998; see Baum, p 15). However, despite these benefits, there
remain a number of significant clinical issues which may limit
tamoxifen’s long-term use. 
Many of these concerns have centred primarily on tamoxifen’s
partial agonist activity. While offering benefits to bone mineral
density and blood lipid profiles, this agonistic activity has also
been associated with detrimental effects upon the endometrium
(Assikis and Jordan, 1995) and increases the risk of thrombo-
embolic disease in some patients. Furthermore, it is thought that
the development of tamoxifen resistance necessitating furthe
therapies is due, in part, to this partial agonist activity (Plotkin
et al, 1978; Howell et al, 1995a). 
Consequently, success in identifying an improved endocrine
agent is reliant upon resolving these negative trophic effects, while
maintaining or perhaps improving on the advantages that tamox-
ifen offers. To achieve this end, recent attention has focused on
the third-generation aromatase inhibitors, including anastrozole
(‘ArimidexTM’), which exert their clinical effects by blocking the
peripheral production of oestrogens and thus significantly impact
on total circulating oestrogens. The aromatase enzyme converts
androgen substrates to oestrogen, the primary source of the
hormone in postmenopausal women. However, aromatase
inhibitors cannot abrogate the trophic actions of dietary or
environmental oestrogens. 
A third class of agents currently attracting significant clinical
interest are the oestrogen receptor (ER) down-regulators, which
act by completely suppressing the effects of oestrogens as a
consequence of disrupted nuclear localization of ligand–ER
complexes and increased proteolytic degradation of the ER
(Howell et al, 2000a). ICI 182,780 (Fulvestrant™) is the first
agent to be identified in this class and may represent an important
advance in endocrine therapy. Acting as a ‘pure’ antioestrogen,
ICI 182,780 lacks any partial agonist activity. Consequently, it is
expected that ICI 182,780 may offer a longer duration of treatment
response with a decreased risk of thromboembolism and the
unwanted endometrial side-effects that have been associated with
tamoxifen treatment in some patients. ICI 182,780 is currently
being clinically evaluated in global phase III trials.
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Summary ICI 182,780 (Fulvestrant™) is the first in a new class of novel, steroidal, ‘pure’ antioestrogens – the oestrogen receptor (ER) down-
regulators. Its unique mode of action and the absence of partial agonist activity make it a candidate for the treatment of advanced breast
cancer in both pre- and postmenopausal women. Tamoxifen has been available for use over the past 25 years. However, its partial agonist
activity has been associated with detrimental effects, particularly on the endometrium, and may be associated with the development of
tamoxifen resistance. Other antioestrogen agents have previously been unable to demonstrate clinically relevant activity following the
development of resistance to tamoxifen. In contrast, the unique mechanism of action of ICI 182,780 results in significant clinical activity in
patients failing on tamoxifen therapy. Indeed, phase III clinical trials have demonstrated that ICI 182,780 is at least as effective as the
aromatase inhibitor anastrozole in the treatment of postmenopausal patients with advanced disease who have progressed during threatment
with prior enocrine therapy. As such, ICI 182,780 will provide a valuable addition to the armamentarium for the treatment of advanced breast
cancer. © 2001 Cancer Research Society 
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A NOVEL MODE OF ACTION 
The majority of antioestrogens that have been identified to date,
including tamoxifen, are predominantly nonsteroidal in structure.
In contrast, ICI 182,780 is an oestrogen analogue compound with
an alkylsulphinyl side-chain at position 7α (Figure 1). This
compound was identified in the late 1980s in a systematic
programme to identify agents which completely blocked oestra-
diol-stimulated uterine proliferation in the rat without stimulating
proliferation in the absence of oestrogen, indicating a pure anti-
oestrogenic activity (Wakeling et al, 1991). ICI 182,780 as been in
clinical development since the early 1990s. 
In addition to structural distinctions, ICI 182,780 also differs
from tamoxifen in its novel mode of action. Although both agents
mediate their clinical effects through the ER, they differ signifi-
cantly in the downstream sequence of events after binding.
Oestradiol, the natural ligand for the ER, binds and stimulates
receptor dimerization and subsequent activation of two activation
domains (AF1 and AF2, Figure 2). The activated receptor complex
then undergoes nuclear localization and subsequent binding to
discrete DNA sequences – oestrogen response elements (EREs) –
located in the upstream regulatory regions of oestrogen-regulated
genes. Upon binding to these sequences, transcriptional coactiva-
tors are recruited to the complex, resulting in activation of gene
expression. In contrast, tamoxifen binds to the ER and dimeriza-
tion occurs but fails to activate the AF2 domain (Figure 2).
Ultimately, this causes incomplete attenuation of transcription and
thus, while tamoxifen exerts antioestrogen activity, the active AF1
domain allows a degree of gene expression to occur, resulting in
tamoxifen’s partial agonist activity. In contrast, while ICI 182,780
is capable of binding to the ER, receptor dimerization is impaired,
receptor degradation is accelerated by increase of receptor protein
turnover, and AF1 and AF2 remain inactive. Ultimately, this
results in disrupted nuclear localization and a failure to recruit
transcriptional coactivators. Consequently, ER-mediated transcription
is completely attenuated, leading to complete suppression of the
expression of oestrogen-dependent genes, and thus ICI 182,780
can be described as a ‘pure antioestrogen’ (Wakeling, 1995). 
PRECLINICAL DATA 
Early evidence from preclinical animal models provided the first
data indicating that ICI 182,780 may offer a potential therapeutic
advance over tamoxifen. In addition, these studies have also
provided strong supporting evidence for ICI 182,780’s unique
mechanism of action. Early observations from oestrogen receptors
in the rat uterus demonstrated that ICI 182,780 has a greater
binding affinity for the ER than tamoxifen (Wakeling et al, 1991).
In vivo models have shown that ICI 182,780 is effective in
inhibiting the growth of tamoxifen-resistant (Coopman et al, 1994)
and tamoxifen-stimulated cell lines (Osborne et al, 1994). In nude
mice xenografted with MCF-7 tumour cells, superior efficacy of
ICI 182,780 was demonstrated by showing a near-doubling of the
mean duration of tumour control compared with both tamoxifen
and oestrogen withdrawal (Figure 3) (Osborne et al, 1995).
Moreover, some of the tumours examined in this study did not
re-grow, even 2 years after initial follow-up. Animal models have
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Figure 1 ICI 182,780, a steroidal oestrogen receptor down-regulator 
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Figure 2 Mechanisms of action – oestradiol, tamoxifen and ICI 182,780. Each antioestrogen differs in the mode of action at the level of the oestrogen receptor
(ER). Molecular events that normally occur include receptor dimerization and binding to discrete oestrogen-response elements in oestrogen-regulated genes,
followed by recruitment of other proteins to form a transcriptional complex, leading to either transcriptional activation or repression (adapted with kind
permission from the Society of Endocrinology from Wakeling 2000) ER = oestrogen receptor, ERE = oestrogen-response elements, AF = activation function,
RNA POL II = RNA polymerase II, E = oestradiol, N = Nolvadex (tamoxifen), F = Fulvestrant (ICI 182,780) also shown that ICI 182,780 probably does not cross the
blood–brain barrier (Wade et al, 1993), thereby potentially mini-
mizing hot flushes in patients. Furthermore, these models have
demonstrated that not only does ICI 182,780 have no proliferative
effect on the uterus, but it also blocks tamoxifen’s uterotrophic
activity (Wakeling et al, 1991). 
CLINICAL DATA 
Presurgical trials 
A large-scale trial of patients scheduled to undergo surgery for
removal of primary breast tumours compared the antitumour
effects of ICI 182,780 with those of tamoxifen (Robertson et al,
2000). A total of 200 postmenopausal women with primary breast
cancer were randomized to receive a range of doses of ICI 182,780
(50–250 mg) administered intramuscularly, or a daily oral dose of
tamoxifen (20 mg/day) or matching tamoxifen placebo for 14–21
days prior to surgery. 
This study demonstrated a clear dose-dependent reduction in the
levels of ER expression, as determined by the ER index. The
reduction in ER index was significantly different from placebo at
the three doses of ICI 182,780 administered. When the clinically
used dose of ICI 182,780 (250 mg) was compared with tamoxifen,
a significantly greater reduction in the ER index was observed
(P = 0.02), indicating greater activity for ICI 182,780. All doses of
ICI 182,780 significantly reduced progesterone receptor (PgR)
expression – an oestrogen-regulated gene – in a dose-dependent
manner. Compared with placebo, the two higher doses of ICI
182,780 (125 and 250 mg) significantly reduced PgR expression.
All three doses of ICI 182,780 reduced progesterone receptor
expression to a greater extent than tamoxifen, which actually
resulted in a stimulation of PgR expression. Ki67 levels, a cell
cycle marker of proliferation, were significantly reduced at all
three ICI 182,780 doses (50, 125 and 250 mg) compared with
placebo, suggesting a potent antiproliferative effect of ICI
182,780. 
This is the first clinical evidence in human breast cancer consis-
tent with preclinical data that also supported the hypothesis of two
distinct mechanisms of action for the two agents. This study also
offers direct evidence in support of the concept that ICI 182,780 is
a functional ER down-regulator in vivo and that it provides signif-
icant and potent antioestrogenic and antiproliferative activities. 
The clinical efficacy of ICI 182,780 has been observed in other
clinical trials. A phase II study was conducted involving 19 post-
menopausal women with advanced breast cancer whose disease
had progressed after prior treatment with tamoxifen. In total 69%
of patients had tumour remission after treatment with 250 mg per
month ICI 182,780 with either an objective response (OR) or
stable disease for more than 24 weeks (SD ≥ 24 weeks). In this
group of patients, the median duration of objective response was
26 months (Howell et al, 1995b; Robertson et al, 1997). In addi-
tion, this initial trial provided important evidence that ICI 182,780
was well tolerated with no increase in deaths, withdrawals or
significant serious adverse events reported. Thus, this trial clearly
demonstrated absence of cross-resistance between tamoxifen and
ICI 182,780, supporting observations made in the earlier preclin-
ical studies. This observation adds further evidence distinguishing
ICI 182,780 from other antioestrogens. 
ICI 182,780 phase III trials 
The early presurgical and phase II clinical trials supported the
initiation of a major phase III clinical programme in post-
menopausal women with advanced breast cancer whose disease
had progressed during or after prior endocrine therapy (the
majority of patients (98%) had received prior tamoxifen treat-
ment). Two phase III, randomized, parallel-group studies (North
American (NA; n = 400) (Osborne et al, 2001) and rest of the
world (ROW; n = 451) (Howell et al, 2000b)) compared the effi-
cacy and tolerability of 250 mg of ICI 182,780 with the aromatase
inhibitor anastrozole, 1 mg, in the treatment of advanced breast
cancer. In essence, these trials compared the efficacy of an anti-
oestrogen (ICI 182,780) administered after the failure of another
antioestrogen (tamoxifen) with the efficacy of an aromatase
inhibitor (anastrozole) given after an antioestrogen. This is partic-
ularly interesting given the recent observation that demonstrates a
superior efficacy of anastrozole compared with tamoxifen in the
treatment of advanced disease. Anastrozole was the first aromatase
inhibitor to be licensed for first-line treatment in advanced breast
cancer (see Buzdar, p 6). 
Both trials were virtually identical in their design. However,
there were some notable differences between the two. Firstly, the
ROW trial had an open, non-blinded design while the NA study
was performed under double-blind, double-dummy conditions (by
employing an ICI 182,780 placebo injection in the anastrozole
group and placebo anastrozole tablets in the ICI 182,780 group).
Secondly, the NA trial delivered two 2.5 ml injections of ICI
182,780, while the ROW trial employed only a single 5 ml
injection. 
Time to progression (TTP), the primary efficacy end-point, was
not significantly different between the ICI 182,780 and anastrozole
arms of both trials (NA trial: median TTP 5.4 months vs 3.4
months, HR 0.92 (0.74–1.14) P = 0.43; ROW: 167 days vs 156
days, HR 0.98 (0.80, 1.21), P = 0.84). The OR (complete response
(CR) + partial response (PR) rate in the ROW trial was 20.7% in
the ICI 182,780 group compared with the anastrozole arm (15.7%,
P = 0.20). Clinical benefit (CR + PR + SD ≥ 24 weeks) was similar
in both treatment arms (approximately 45%). In the NA trial the
OR was identical in both treatment arms (17.5%, P = 0.96) and
there was a 5% greater clinical benefit with ICI 182,780 (42%)
compared with anastrozole (36%). 
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Figure 3 Effects of oestrogen withdrawal, tamoxifen and ICI 182,780 on
MCF-7 tumour growth (adapted with kind permission from Oxford University
Press from Osborne et al, 1995) When specific consideration was given only to those patients
who had responded to endocrine treatment, a near-doubling of
tumour response time was observed in the double-blind NA trial
(median duration of response (DOR) 19.3 months with ICI
182,780 vs 10.5 months with anastrozole in the NA trial). In the
ROW trial a similar median DOR for both treatments was
observed (434 days vs 425 days). In summary, ICI 182,780 was 
at least as effective as anastrozole for all major primary and
secondary efficacy end-points in the management of advanced
breast cancer. 
Data from the NA and ROW studies indicate that both ICI
182,780 and anastrozole are generally well tolerated in these
women, which is particularly encouraging given the longer clinical
experience with anastrozole. Similar numbers of patients in both
studies withdrew due to an adverse event (3.2% vs 2.2% for ICI
182,780 and anastrozole in the ROW trial; 2.5% vs 2.6% in the
NA trial). In the ROW trial, predefined adverse events for ICI
182,780 and anastrozole included: hot flushes (18.6% vs 17%),
gastrointestinal disturbances (40.0% vs 34.3%), weight gain (0.5%
vs 1.7%) and vaginitis (0.5% vs 0.9%). In the NA trial, these
predefined events were: hot flushes (23.5% vs 24.9%), gastro-
intestinal disturbances (53.4% vs 56.0%), weight gain (1.5% vs
1.6%) and vaginitis (3.4% vs 2.6%). Data from both trials indicate
that the injection of ICI 182,780 was well tolerated. 
CONCLUSION 
Currently, tamoxifen is the most widely used agent for the treat-
ment of advanced breast cancer. While aromatase inhibitors offer
further clinical benefit following tamoxifen failure, alternative
antioestrogens offer little if any clinical benefit. In contrast, the ER
downregulator ICI 182,780, is highly effective in the treatment of
postmenopausal patients with advanced breast cancer who have
progressed on prior endocrine therapy. Indeed the clinical trial
programme indicates that ICI 182,780 is at least as effective as
anastrozole. Given the efficacy and tolerability it has demonstrated
so far, combined wiith the convenience of a once-monthly intra-
muscular injection, ICI 182,780 provides a valuable addition to the
currently available options for the treatment of advanced breast
cancer.
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